Welcome to our dedicated page for Corvus Pharmaceuticals SEC filings (Ticker: CRVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Corvus Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Corvus Pharmaceuticals's regulatory disclosures and financial reporting.
Corvus Pharmaceuticals, Inc. reported the results of its 2026 Annual Meeting of Stockholders, where stockholders voted on director elections, auditor ratification, and executive compensation.
Two Class I directors, Richard A. Miller, M.D., and Linda S. Grais, M.D., J.D., were elected to serve until the 2029 annual meeting. Stockholders also ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. In addition, on a non-binding advisory basis, stockholders approved the compensation of the company’s named executive officers. A total of 73,021,854 shares of common stock were voted out of 84,090,424 shares outstanding as of the April 16, 2026 record date.
Corvus Pharmaceuticals, Inc. President and CEO Dr. Richard A. Miller reported additional open-market purchases of the company’s common stock. Through the Miller-Horning Family Trust, where he shares voting and investment power, the trust bought 1,932 shares at $12.01 per share and 5,000 shares at $12.05 per share on May 18, 2026, totaling 6,932 shares. After these transactions, he reports 1,136,707 shares held directly and 1,195,035 shares held indirectly through the trust.
Corvus Pharmaceuticals, Inc. Amendment No. 1 to a Schedule 13G/A reports that Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen held 0% of the company's common stock as of the close of business on 03/31/2026. The cover page entries show zero voting and dispositive power for the reporting persons on that date.
Corvus Pharmaceuticals Schedule 13G: Sirenia Capital Management and Alex Silverstein report beneficial ownership of 6,831,828 shares of Common Stock issuable upon exercise of warrants, representing 7.5% of the class. This percentage is calculated using March 12, 2026 outstanding shares of 83,992,407 and assumes exercise of the warrants.
The filing states the shared voting and dispositive power over the 6,831,828 warrant-issuable shares and attaches a Joint Filing Agreement as Exhibit 99.1.
Corvus Pharmaceuticals reported final results from a randomized, blinded, placebo-controlled Phase 1 trial of oral ITK inhibitor soquelitinib in 72 patients with moderate-to-severe atopic dermatitis who had failed at least one prior topical or systemic therapy. Thirty-five percent had previously received systemic treatment, yet the drug showed dose-dependent efficacy and additional benefit with longer dosing. In the 200 mg twice-daily cohorts, 50% (cohort 3) and 75% (cohort 4) of patients reached EASI 75, with higher response rates in the longer 56-day cohort and durable disease control through 30–90 days of drug-free follow up without rebound or need for rescue medication. Safety appeared favorable, with adverse events in 41.7% of both soquelitinib and placebo groups, all Grade 1–2, no serious events, and no significant lab abnormalities. Extensive biomarker work suggested soquelitinib modulates Th2/Th17 pathways, increases persistent Treg cells, and affects JAK-STAT signaling, aligning with its proposed mechanism. Corvus is now enrolling a roughly 200-patient Phase 2 SIERRA1 trial in atopic dermatitis, while partner Angel Pharmaceuticals runs a parallel Phase 1b/2 study in China.
Corvus Pharmaceuticals reported a net loss of $13.7 million for the three months ended March 31, 2026, or $0.15 per basic and diluted share, compared with net income of $15.2 million a year earlier driven by a $25.1 million noncash gain from warrant revaluation. Operating expenses rose to $14.9 million as the company advanced its ITK inhibitor soquelitinib into a Phase 3 trial in relapsed peripheral T cell lymphoma and a Phase 2 trial in atopic dermatitis, and continued development of ciforadenant and mupadolimab. A January 2026 follow-on public offering of 9.1 million shares generated net proceeds of $189.4 million, lifting cash, cash equivalents and marketable securities to $236.7 million and extending the estimated cash runway into the second quarter of 2028.
Corvus Pharmaceuticals reported first quarter 2026 results and a major strengthening of its balance sheet while advancing its lead ITK inhibitor, soquelitinib. Cash, cash equivalents and marketable securities rose to $236.7 million as of March 31, 2026, including $189.4 million in net financing proceeds completed in January. Management believes this will fund operations into the second quarter of 2028.
R&D expenses increased to $11.2 million from $7.5 million a year earlier, mainly from higher soquelitinib clinical trial and personnel costs. The company posted a net loss of $13.7 million, versus net income of $15.2 million in 2025 that was driven by a large non-cash warrant liability revaluation.
Corvus initiated a Phase 2 atopic dermatitis trial for soquelitinib, continues a registrational Phase 3 trial in relapsed/refractory peripheral T cell lymphoma, and is preparing additional Phase 2 studies in hidradenitis suppurativa and asthma, highlighting a broader immune-disease strategy around ITK inhibition.
Corvus Pharmaceuticals director Andrew C. Chan received a grant of stock options for 30,000 shares of common stock. The options have an exercise price of $16.02 per share and expire on April 23, 2036. All 30,000 options were reported as directly owned following the grant.
The footnote explains that these options vest in three equal annual installments. One-third of the shares subject to the option will vest on each annual anniversary starting April 23, 2026, as long as Chan continues his service relationship with Corvus on each vesting date.
Corvus Pharmaceuticals, Inc. director Andrew C. Chan filed a Form 3, which is an initial statement of beneficial ownership for insiders. The filing lists him as a director and shows no reportable insider transactions, purchases, or sales at this time.
BlackRock, Inc. amends a Schedule 13G to report ownership of 5,387,818 shares of Corvus Pharmaceuticals common stock, representing 6.4% of the class. The filing shows sole voting power for 5,320,965 shares and sole dispositive power for 5,387,818 shares as reported on 04/27/2026.
The amendment cites aggregated holdings across BlackRock reporting business units and notes various clients/beneficiaries may have rights to dividends or proceeds. Exhibit references include a Power of Attorney and an Item 7 exhibit identifying relevant subsidiaries.